Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
16881
Table 5_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev...
Published 2025“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
-
16882
Table 4_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev...
Published 2025“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
-
16883
Table 2_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev...
Published 2025“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
-
16884
Table 3_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev...
Published 2025“…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
-
16885
Table 4_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16886
Data Sheet 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.doc
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16887
Table 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16888
Table 7_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16889
Table 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16890
Table 3_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16891
Data Sheet 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.docx
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16892
Table 6_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16893
Table 5_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls
Published 2025“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
-
16894
Table_1_Exploring the potential role of microbiota and metabolites in acute exacerbation of chronic obstructive pulmonary disease.pdf
Published 2024“…However, the relative abundance of Haemophilus_D, Veillonella_A and Pseudomonas_E, in AECOPD patients was significantly higher than that of COPD patients, and the ability of respiratory microbiota in AECOPD patients to participate in alanine metabolism was significantly lower than that of COPD patients. …”
-
16895
Table_3_Exploring the potential role of microbiota and metabolites in acute exacerbation of chronic obstructive pulmonary disease.pdf
Published 2024“…However, the relative abundance of Haemophilus_D, Veillonella_A and Pseudomonas_E, in AECOPD patients was significantly higher than that of COPD patients, and the ability of respiratory microbiota in AECOPD patients to participate in alanine metabolism was significantly lower than that of COPD patients. …”
-
16896
Table_2_Exploring the potential role of microbiota and metabolites in acute exacerbation of chronic obstructive pulmonary disease.pdf
Published 2024“…However, the relative abundance of Haemophilus_D, Veillonella_A and Pseudomonas_E, in AECOPD patients was significantly higher than that of COPD patients, and the ability of respiratory microbiota in AECOPD patients to participate in alanine metabolism was significantly lower than that of COPD patients. …”
-
16897
Table 6_Analyze agricultural efficiency and influencing factors base on the three-stage DEA model and Malmquist index.xlsx
Published 2025“…Thus, geographical environments and variations also exert significant impacts on agricultural efficiency. Meanwhile, enhancing agricultural production efficiency is of paramount importance for ensuring food security and promoting sustainable rural development. …”
-
16898
Table 7_Analyze agricultural efficiency and influencing factors base on the three-stage DEA model and Malmquist index.xlsx
Published 2025“…Thus, geographical environments and variations also exert significant impacts on agricultural efficiency. Meanwhile, enhancing agricultural production efficiency is of paramount importance for ensuring food security and promoting sustainable rural development. …”
-
16899
Table 5_Analyze agricultural efficiency and influencing factors base on the three-stage DEA model and Malmquist index.xlsx
Published 2025“…Thus, geographical environments and variations also exert significant impacts on agricultural efficiency. Meanwhile, enhancing agricultural production efficiency is of paramount importance for ensuring food security and promoting sustainable rural development. …”
-
16900
Table 3_Analyze agricultural efficiency and influencing factors base on the three-stage DEA model and Malmquist index.xlsx
Published 2025“…Thus, geographical environments and variations also exert significant impacts on agricultural efficiency. Meanwhile, enhancing agricultural production efficiency is of paramount importance for ensuring food security and promoting sustainable rural development. …”